KR20240008231A - 급성호흡곤란증후군의 치료 또는 예방 방법 - Google Patents
급성호흡곤란증후군의 치료 또는 예방 방법 Download PDFInfo
- Publication number
- KR20240008231A KR20240008231A KR1020227046116A KR20227046116A KR20240008231A KR 20240008231 A KR20240008231 A KR 20240008231A KR 1020227046116 A KR1020227046116 A KR 1020227046116A KR 20227046116 A KR20227046116 A KR 20227046116A KR 20240008231 A KR20240008231 A KR 20240008231A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- csf
- dose
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Storage Of Fruits Or Vegetables (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901843A AU2020901843A0 (en) | 2020-06-04 | Method of treating or preventing acute respiratory distress syndrome | |
| PCT/AU2021/050568 WO2021243424A1 (en) | 2020-06-04 | 2021-06-07 | Method of treating or preventing acute respiratory distress syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240008231A true KR20240008231A (ko) | 2024-01-18 |
Family
ID=78830044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227046116A Pending KR20240008231A (ko) | 2020-06-04 | 2021-06-07 | 급성호흡곤란증후군의 치료 또는 예방 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12583929B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161576A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023533658A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240008231A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768475A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021285088A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175686A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021243424A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024003788A1 (en) * | 2022-06-29 | 2024-01-04 | Novocure Gmbh | Treating acute respiratory distress syndrome with alternating electric fields |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU3691093A (en) | 1992-04-14 | 1993-10-21 | Hybritech Incorporated | Methods of inhibiting the growth of multidrug resistant tumors |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| CA2145278C (en) | 1992-09-25 | 2009-03-10 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| AUPM375194A0 (en) | 1994-02-08 | 1994-03-03 | Ludwig Institute For Cancer Research | Cytokine receptor interactive molecules |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
| DK1068311T3 (da) | 1998-04-08 | 2011-08-08 | Commw Scient Ind Res Org | Fremgangsmåder og midler til opnåelse af modificerede fænotyper |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP2000319298A (ja) | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| AUPR544401A0 (en) | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| DK1751181T3 (da) | 2004-06-02 | 2012-11-26 | Adalta Pty Ltd | BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007025166A2 (en) | 2005-08-25 | 2007-03-01 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
| CA2654894A1 (en) | 2006-07-06 | 2008-10-01 | Laboratoires Serono S.A. | Csf3r polypeptides and uses thereof |
| AU2007283463B2 (en) | 2006-08-11 | 2012-04-26 | Csl Limited | Treatment of pulmonary disease conditions |
| US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| CL2008002782A1 (es) | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法 |
| FR2950381B1 (fr) | 2009-09-18 | 2011-10-28 | Snecma | Turbomachine a helices non carenees contrarotatives |
| US8968731B2 (en) | 2009-10-09 | 2015-03-03 | Csl Limited | Treatment of uveitis |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| EP2367000A1 (en) | 2010-03-04 | 2011-09-21 | Charité Universitätsmedizin Berlin | High throughput analysis of T-cell receptor repertoires |
| CN102869777B (zh) | 2010-04-02 | 2018-11-02 | 库尔纳公司 | 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病 |
| AU2011319746B2 (en) | 2010-10-27 | 2015-07-30 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type I (sCR1) |
| EP2675471A4 (en) | 2011-02-15 | 2015-01-28 | Medimmune Llc | HSA-RELATED COMPOSITIONS AND USE PROCESSES |
| RU2605595C2 (ru) | 2011-06-13 | 2016-12-20 | СиЭсЭл Лимитид | Антитела против g-csfr и их применение |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| US9050305B2 (en) | 2012-03-29 | 2015-06-09 | Chs Pharma, Inc. | Treatment for ischemic stroke |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
| EP3063171B1 (en) | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック, インコーポレイテッド | 抗il−13/il−17二重特異性抗体及びその使用 |
| EP3220952B1 (en) | 2014-11-17 | 2021-04-21 | CSL Limited | Method of treating or preventing stroke |
| EP3445450A4 (en) | 2016-04-21 | 2020-01-08 | CSL Limited | METHOD FOR TREATING OR PREVENTING LIVER DISEASES |
| US20210179721A1 (en) | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| KR20190073917A (ko) * | 2017-12-19 | 2019-06-27 | 포항공과대학교 산학협력단 | 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물 |
| US12281160B2 (en) * | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体および抗pd-1抗体の共-製剤 |
| BR112021010920A2 (pt) * | 2018-12-04 | 2021-08-31 | CSL Innovation Pty Ltd | Método de tratamento de condições neutrofílicas |
| KR20220019806A (ko) * | 2019-06-12 | 2022-02-17 | 씨에스엘 이노베이션 피티와이 엘티디 | 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도 |
| US20240002517A1 (en) * | 2020-12-16 | 2024-01-04 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
-
2021
- 2021-06-07 CN CN202180036037.8A patent/CN115768475A/zh active Pending
- 2021-06-07 US US18/000,153 patent/US12583929B2/en active Active
- 2021-06-07 CA CA3175686A patent/CA3175686A1/en active Pending
- 2021-06-07 KR KR1020227046116A patent/KR20240008231A/ko active Pending
- 2021-06-07 AU AU2021285088A patent/AU2021285088A1/en active Pending
- 2021-06-07 WO PCT/AU2021/050568 patent/WO2021243424A1/en not_active Ceased
- 2021-06-07 EP EP21818292.1A patent/EP4161576A4/en active Pending
- 2021-06-07 JP JP2022574594A patent/JP2023533658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230272087A1 (en) | 2023-08-31 |
| CN115768475A (zh) | 2023-03-07 |
| US12583929B2 (en) | 2026-03-24 |
| AU2021285088A1 (en) | 2023-01-05 |
| CA3175686A1 (en) | 2021-12-09 |
| WO2021243424A1 (en) | 2021-12-09 |
| EP4161576A1 (en) | 2023-04-12 |
| JP2023533658A (ja) | 2023-08-04 |
| EP4161576A4 (en) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210079105A1 (en) | Methods of Treating Inflammatory Conditions | |
| RU2734490C2 (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| EP3010539B1 (en) | Methods for treating nasal polyposis by administering an il-4r antagonist | |
| KR102887037B1 (ko) | 호중구 질환을 치료하는 방법 | |
| JP2021501169A (ja) | Il−4r拮抗薬の投与により喘息を処置または予防するための方法 | |
| US12281160B2 (en) | Method of treating asthma | |
| SG11202111255YA (en) | Methods for treating or preventing asthma by administering an il-33 antagonist | |
| TWI745962B (zh) | 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法 | |
| TW202134273A (zh) | 藉由投予il-33拮抗劑治療copd的方法 | |
| US12583929B2 (en) | Method of treating acute respiratory distress syndrome | |
| US20230416381A1 (en) | Methods for treating or preventing acute respiratory distress syndrome | |
| US12357689B2 (en) | Methods of treating or preventing a cardiovascular system complication of sickle cell disease with an anti-G-CSFR antibody | |
| CN117062609A (zh) | 用于治疗或预防急性呼吸窘迫综合征的方法 | |
| WO2025217677A1 (en) | Methods for treating neutrophilic skin conditions | |
| WO2025120567A1 (en) | Method of treatment of asthma | |
| WO2025217678A1 (en) | Methods of treating or delaying progression or hindering development of a neutrophil-associated condition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |